Fluoroquinolones are bactericidal antimicrobials widely used in veterinary medicine. Nalidixic acid, the first antibacterial quinolone developed for clinical use and the precursor to other fluoroquinolones, was discovered in 1962 and approved for clinical use in 1967.1,2 Quinolone carboxylic acid derivatives have a broad spectrum of activity against gram-positive and gram-negative bacteria as well as Mycoplasma organisms.2 Quinolones inhibit bacterial DNA gyrase and deactivate bacterial enzymes necessary for the transcription of DNA. This results in uncoiling of DNA and interference of bacterial DNA synthesis, repair, recombination, and transposition.3–11 The DNA segments become unreadable, and the bacterial cell dies.
Fluoroquinolones are excreted by renal and hepatic routes. Toxic effects of fluoroquinolones in mammalian cells are low compared with toxic effects in bacterial cells because the enzyme analogue to bacterial DNA gyrase in eukaryotes is 100 to 1,000 times less susceptible to gyrase inhibitors.12
Enrofloxacin was approved for use in cats in the United States in 1990 at a dosage of 2.5 mg/kg, PO.a,b Enrofloxacin is also approved in the United States for use in dogs and cattle. Prior to FDA approval, enrofloxacin underwent mandatory toxicologic testing in dogs and cats. Preapproval safety studies conducted in 1989 in dogs and cats revealed the product was safe when administered at a dosage of 25 mg/kg/d for 30 days.a In 1992, the general safety of enrofloxacin in young cats was determined at dosages of 5, 15, and 25 mg/kg; there was no evidence of adverse effects.13 Subsequently, in 1997, a flexible dosing regimen of 5 to 20 mg/kg, PO, once daily or as a divided dose was recommended.14,a Once-daily dosing of enrofloxacin was widely accepted after pharmacologic testing revealed that such use achieved higher peak plasma drug concentrations, increased bactericidal efficacy, decreased risk of bacterial resistance, and provided increased ease of administration.14 After introduction of this flexible dosing regimen, veterinarians reported an increased incidence of vision-related problems that resulted after once-daily oral administration of enrofloxacin. These problems included blindness, partial blindness, and mydriasis.14–19,a In 2 reports15,16 published between 1999 and 2001, investigators suggested a possible link between enrofloxacin administration and vision problems in cats.
In response to the increased incidence of visionrelated problems, the manufacturer enlisted input and expertise from members of the American College of Veterinary Ophthalmologists to determine the best means to objectively investigate this matter. A specific safety study was performed to assess potential effects of enrofloxacin on ocular variables in cats. In June 2000, a postapproval studyc was conducted in which doses of 5, 20, and 50 mg/kg, PO, were administered once daily. In that study, investigators observed dose-related ocular effects attributable to enrofloxacin, with the most severe ocular effects in cats administered 50 mg/kg/d (ie, 2.5 times the high end of the approved dosage range) and with fundic signs that developed within 1 week after onset of administration. No changes were observed in cats administered 5 mg/kg/d (ie, the low end of the approved dosage range). In 2001, the drug label was revised to reflect an FDA-approved dosage for oral administration of 5 mg/kg/d in cats.19
A link between enrofloxacin administration and visual deficits in cats has been established, but little is known concerning the mechanisms by which enrofloxacin causes visual compromise. The proven usefulness of fluoroquinolones in the management of cats with a wide array of diseases ensures their continued, common use in veterinary medicine. The objective of the study reported here was to determine the clinical, funduscopic, electroretinographic, and histologic effects of oral administration of a high dose of enrofloxacin on the retinas of clinically normal cats.
Schirmer tear test
Retinal pigmented epithelium
Photoreceptor outer segment
Photoreceptor inner segment
Outer nuclear layer
Outer plexiform layer
Evans E, Bayer Health Care LLC, Animal Health Division, Shawnee Mission, Kan. Personal communication, 2000, 2001.
Baytril, Shawnee Mission, Kan.
Bayer Health Care LLC, Animal Health Division, Shawnee Mission, Kan: Corporate data.
Liberty Research Inc, Waverly, NY.
Parks Medical Doppler ultrasound, model 811.B, Aloha, Ore.
Finnoff transilluminator, Welch Allyn Distributors, Skaneateles Falls, NY.
Schirmer tear test standardized strips, Schering-Plough Animal Health, Omaha, Neb.
Tono-Pen XL, Mentor O&O Inc, Norwell, Mass.
Fluor-I-Strips AT, Ayerst Laboratories, New York, NY.
Slitlamp biomicroscope, SL14, KOWA Co Ltd, Tokyo, Japan.
All-pupil indirect ophthalmoscope, Keeler Instruments Inc, Broomhall, Pa.
Volk double aspheric lens, 20 diopter, Veatch Ophthalmic Instruments, Tempe, Ariz.
Nidek NM-100 hand-held digital fundus camera, Nidek Co Ltd, Freemont, Calif.
Domitor (Medetomidine), Novartis, Pfizer Animal Health, Exton, Pa.
Ketaset III, Fort Dodge Animal Health, Fort Dodge, Iowa.
ERG jet electrodes, LKC Technologies Inc, Gaithersburg, Md.
Grass telefactor subdermal needle electrodes, model E2, AstroMedica, West Warwick, RI.
ERG System TOR, Global Eye Program, Rejmyre, Sweden.
Kodak Wratten neutral density filters No. 96, Eastman Kodak Co, Rochester, NY.
Beuthanasia-D-Special, Schering Plough Animal Health, Omaha, Neb.
Epon-araldite resin, Electron Microscopy Sciences, Hatfield, Pa.
PROC Freq, version 9.1, SAS Institute Inc, Cary, NC.
Lesher GY, Froelich EJ, Gruett MD, et al. 1-8 naphthyridine derivatives. A new class of chemotherapeutic agents. J Med Pharm Chem 1962;91:1063–1065.
Gootz T, Brighty K. Fluoroquinolone antibacterials: SAR mechanism of action, resistance, and clinical aspects. Med Res Rev 1996;16:433–486.
Gellert M, Mizzuchi K, O’Dea MH, et al. Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity. Proc Natl Acad Sci U S A 1977;74:4772–4776.
Gellert M, Mizuuchi K, O’Dea MH, et al. DNA gyrase: an enzyme that introduces superhelical turns into DNA. Proc Natl Acad Sci U S A 1976;73:3872–3876.
Wiebe V, Hamilton P. Fluoroquinolone-induced retinal degeneration in cats. J Am Vet Med Assoc 2002;221:1568–1571.
Gelatt K, van der Woerdt A, Ketring KL, et al. Enrofloxacin-associated retinal degeneration in cats. Vet Ophthalmol 2001;4:99–106.
Giuliano E, van der Woerdt A. Feline retinal degeneration: clinical experience and new findings (1994–1997). J Am Anim Hosp Assoc 1999;35:511–514.
Hampshire VA, Doddy FM, Post LO, et al. Adverse drug event reports at the United States Food and Drug Administration Center for Veterinary Medicine. J Am Vet Med Assoc 2004;225:533–536.
Narfström K, Ekesten B, Rosolen SG, et al. Committee for the Harmonized ERG Protocol, European College of Veterinary Ophthalmology. Guidelines for clinical electroretinography in the dog. Doc Ophthalmol 2002;105:83–92.
Stokes ME, Davis CS, Koch GG. In: Hoaglin DC, Mosteller F, Tukey JW, eds. Categorical data analysis using the SAS system. 2nd ed. Cary, NC: SAS Institute Inc, 2000.
Hall RL. Leukocyte responses and abnormalities. In: Fenner WR, ed. Quick reference to veterinary medicine. Philadelphia: JB Lippincott Co, 1982;369–371.
Diagnostic procedures for the office laboratory. In: Fraser CM, Mays A, eds. The Merck veterinary manual. Rahway, NJ: Merck & Co Inc, 1986;877–893.
The pancreas (endocrine diseases). In: Fraser CM, Mays A, eds. The Merck veterinary manual. Rahway, NJ: Merck & Co Inc, 1986;266–277.
Ambrisko TD, Hikasa Y. Neurohormonal and metabolic effects of medetomidine compared with xylazine in beagle dogs. Can J Vet Res 2002;66:42–49.
Ambrisko TD, Hikasa Y, Sato K. Influence of medetomidine on stress-related neurohormonal and metabolic effects caused by butorphanol, fentanyl, and ketamine administration in dogs. Am J Vet Res 2005;66:406–412.
Hikasa Y, Hisahiro K, Katsuaki T, et al. Comparisons of sevoflurane, isoflurane, and halothane anesthesia in spontaneously breathing cats. Vet Surg 1996;25:234–243.
Hooper D, Wolfson J. Adverse effects. In: Hooper D, Wolfson J, eds.Quinolone antimicrobial agents. Washington, DC: American Society for Microbiology, 1993;489–512.
Semo M, Peirson S, Lupi D, et al. Melanopsin retinal ganglion cells and the maintenance of circadian and pupillary responses to light in aged rodless/coneless (rd/rd cl) mice. Eur J Neurosci 2003;17:1793–1801.
Gooley J, Lu J, Chou TC, et al. Melanopsin in cells of origin of the retinohypothalamic tract. Nat Neurosci 2001;4:1165.
Scagliotti R. Neuroophthalmology. In: Gelatt K, ed. Veterinary ophthalmology. Baltimore: Lippincott Williams & Wilkins, 1986;1316.
Martin L, Kaswan R, Chapman W. Four cases of optic nerve blindness in the horse. Equine Vet J 1986;18:133–137.
Bhattacherjee P, Paterson CA, Spellman JM, et al. Pharmacological validation of a feline model of steroid-induced ocular hypertension. Arch Ophthalmol 1999;117:361–364.
Miyazaki Y, Matsuo T, Kurabayashi Y. Immobilization stress induces elevation of intraocular pressure in rabbits. Ophthalmic Res 2000;32:270–277.
Li Voon Chong JS, Sen J, Johnson Z, et al. Hydrocortisone replacement dosage influences intraocular pressure in patients with primary and secondary hypocortisolism. Clin Endocrinol (Oxford) 2001;54:267–271.
Narfström K, Ekesten B. Diseases of the canine ocular fundus. In: Gelatt K, ed. Veterinary ophthalmology. Baltimore: Lippincott Williams & Wilkins, 1999;869–933.
Glaze M, Gelatt K. Feline ophthalmology. In: Gelatt K, ed. Veterinary ophthalmology. Baltimore: Lippincott Williams & Wilkins, 1999;997–1052.
Narfström K. Progressive retinal atrophy in the Abyssinian cat: clinical characteristics. Invest Ophthalmol Vis Sci 1985;26:193–200.
Steinberg RH, Reid M, Lacy PL. The distribution of rods and cones in the retina of the cat (Felis domesticus). J Comp Neurol 1973;148:229–248.
Tucker GS, Hamasaki DI, Labbie A, et al. Anatomic and physiologic development of the photoreceptor of the kitten. Exp Brain Res 1979;37:459–474.
Peiffer R, Wilcock B, Dubielzig R, et al. Fundamentals of veterinary ophthalmic pathology. In: Gelatt K, ed. Veterinary ophthalmology. Baltimore: Lippincott Williams & Wilkins, 1999;359–360, 411.
Yu D, Cringle S, Valter K, et al. Photoreceptor death, trophic factor expression, retinal oxygen status, and photoreceptor function in the P23H rat. Invest Ophthalmol Vis Sci 2004;45:2013–2019.
Linsenmeier R. Electrophysiological consequences of retinal hypoxia. Graefes Arch Clin Exp Ophthalmol 1990;228:143–150.
Braun R, Linsenmeier R, Goldstick T. Oxygen consumption in the inner and outer retina of the cat. Invest Ophthalmol Vis Sci 1995;36:542–554.
Padnick-Silver L, Kang-Derwent JJ, Giuliano E, et al. Retinal oxygenation and oxygen metabolism in Abyssinian cats with a hereditary retinal degeneration. Invest Ophthalmol Vis Sci 2006;47:3683–3689.
Alm A, Bill A. The oxygen supply in the retina. II. Effects of high intraocular pressure and of increased arterial carbon dioxide tension on uveal and retinal blood flow in cats. Acta Physiol Scand 1972;84:306–319.
Fain GL, Matthews HR, Cornwall C, et al. Adaptation in vertebrate photoreceptors. Physiol Rev 2001;81:117–151.
Vrabec T, Sergott RC, Jaeger EA, et al. Reversible visual loss in a patient receiving high-dose ciprofloxacin hydrochloride (Cipro). Ophthalmology 1990;97:707–710.
Tsuchiya M, Hayasaka S, Mizuno K. Affinity of ocular acidinsoluble melanin for drugs in vitro. Invest Ophthalmol Vis Sci 1987;28:822–825.
Imai R, Sugimoto S, Ando T, et al. A procedure for recording electroretinogram and visual evoked potential in freely moving cats. J Toxicol Sci 1990;15:263–274.
Narfström K, Nilsson SE. Progressive retinal atrophy in the Abyssinian cat. Electron microscopy. Invest Ophthalmol Vis Sci 1986;27:1569–1576.
Narfström K, Ehinger B, Bruun A. Immunohistochemical studies of cone photoreceptors and cells of the inner retina in feline rod-cone degeneration. Vet Ophthalmol 2001;4:141–145.
Asi H, Perlman I. Relationships between the electroretinogram a-wave, b-wave and oscillatory potentials and their application to clinical diagnosis. Doc Ophthalmol 1992;79:125–139.
Ruether K, Kellner U. Inner retinal function in hereditary retinal dystrophies. Acta Anat (Basel) 1998;162:169–177.
Young RW, Bok D. Participation of the retinal pigmented epithelium in the rod outer segment renewal process. J Cell Biol 1969;42:392–403.
Nomura M, Yamada M, Yamamura H, et al. Ophthalmotoxicity and ototoxicity of the new quinolone antibacterial agent levofloxacin in Long Evans rats. Arzneimittelforschung 1992;43:398–403.
Foote E, Halstenson C. Effects of probenecid and cimetidine on renal disposition of ofloxacin in rats. Antimicrob Agents Chemother 1998;42:456–458.
Sudoh T, Fujimura A, Shiga T, et al. Renal clearance of lomefloxacin is decreased by furosemide. Eur J Clin Pharmacol 1994;46:267–269.
Jaehde U, Sorgel F, Reiter A, et al. Effect of probenecid on the distribution and elimination of ciprofloxacin in humans. Clin Pharmacol Ther 1995;58:532–541.
Przybilla B, Georgii A, Bergner T, et al. Demonstration of quinolone phototoxicity in vitro. Dermatologica 1990;181:98–103.
Sakai H, Mochizuki K, Torisaki M, et al. Nontoxic intravitreal dose of ofloxacin for rabbit retina. Ophthalmic Res 1994;26:344–351.
Cohen RG, Raizman M, Callina C, et al. Retinal safety of oral and topical ofloxacin in rabbits. J Ocul Pharmacol Ther 1997;13:369–379.
Wiechens B, Neuman D, Grammer JB, et al. Retinal toxicity of liposomal incorporated and free ofloxacin after intravitreal injection in rabbit eyes. Int Ophthalmol 1998;22:133–143.
Mochizuki K, Higashide T, Torisaki M, et al. Effects of norfloxacin on the retina in rabbits. Graefes Arch Clin Exp Ophthamol 1995;233:173–180.
Tanahashi T, Mochizuki K, Torisaki M, et al. Effects of intravitreal injection of norfloxacin on the retina in pigmented rabbits. Lens Eye Toxic Res 1992;9:493–503.
Wiechens B, Grammer JB, Johannsen U, et al. Experimental intravitreal application of ciprofloxacin in rabbits. Ophthalmologica 1999;213:120–128.
Marchese AL, Slana VS, Holmes EW, et al. Toxicity and pharmacokinetics of ciprofloxacin. J Ocul Pharmacol 1993;9:69–76.
Rootman DS, Savage P, Hasany SM, et al. Toxicity and pharmacokinetics of intravitreally injected ciprofloxacin in rabbit eyes. Can J Ophthalmol 1992;27:277–282.
Stevens SX, Fouraker BD, Jensen HG. Intraocular safety of ciprofloxacin. Arch Ophthalmol 1991;109:1737–1743.
Shimoda K, Yoshida M, Wagai N, et al. Phototoxic lesions induced by quinolone antibacterial agents in auricular skin and retina of albino mice. Toxicol Pathol 1993;21:554–561.